Related Experiment Video
Updated: Jun 6, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin E-CDK2 interactions and delays cell cycle
Hicham H Baydoun1, Joanna Pancewicz, Xuetao Bai
1University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS 66160, USA.
Background:
Human T-cell leukemia virus type I (HTLV-I) has efficiently adapted to its host and establishes a persistent infection characterized by low levels of viral gene expression and slow proliferation of HTLV-I infected cells over decades. We have previously found that HTLV-I p30 is a negative regulator of virus expression.
Results:
In this study we show that p30 targets multiple cell cycle checkpoints resulting in a delayed entry into S phase. We found that p30 binds to cyclin E and CDK2 and prevents the formation of active cyclin E-CDK2 complexes. In turn, this decreases the phosphorylation levels of Rb and prevents the release of E2F and its transcriptional activation of genes required for G1/S transition. Our studies also show that HTLV-II p28 does not bind cyclin E and does not affect cell cycle progression.
Conclusions:
In contrast to HTLV-I, the HTLV-II-related retrovirus is not oncogenic in humans. Here we report that the HTLV-I p30 delays cell cycle progression while its homologue, HTLV-II p28, does not, providing evidence for important differences between these two related retrovirus proteins.
Insights
Human T-cell leukemia virus type I (HTLV-I) p30 protein inhibits cell cycle progression by preventing cyclin E-CDK2 complex formation. This contrasts with HTLV-II p28, which does not affect the cell cycle, highlighting key differences between these retroviruses.
Area of Science:
- Virology
- Molecular Biology
- Cell Cycle Regulation
Background:
- Human T-cell leukemia virus type I (HTLV-I) establishes persistent infections with slow cell proliferation.
- HTLV-I p30 protein acts as a negative regulator of viral gene expression.
Purpose of the Study:
- To investigate the role of HTLV-I p30 in regulating cell cycle progression.
- To compare the effects of HTLV-I p30 and HTLV-II p28 on cell cycle progression.
Main Methods:
- Investigated p30's interaction with cell cycle proteins.
- Assessed the impact of p30 on cyclin E-CDK2 complex formation.
- Monitored cell cycle progression and gene transcription.
Main Results:
- HTLV-I p30 targets cell cycle checkpoints, delaying entry into S phase.
- p30 binds to cyclin E and CDK2, inhibiting active complex formation.
- This leads to decreased Rb phosphorylation and E2F release, hindering G1/S transition.
- HTLV-II p28 does not bind cyclin E or affect cell cycle progression.
Conclusions:
- HTLV-I p30 significantly delays cell cycle progression.
- HTLV-II p28 lacks this cell cycle inhibitory function.
- These findings reveal critical differences between HTLV-I p30 and HTLV-II p28 proteins.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...

